Immune Design to Present at Jefferies 2017 Global Healthcare Conference
June 01 2017 - 8:00AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on cancer, today announced that Carlos Paya, M.D., Ph.D.,
President and Chief Executive Officer, will present at the
Jefferies 2017 Global Healthcare Conference in New York on
Wednesday, June 7, 2017 at 8 a.m. ET.
A live webcast of the presentation will be available online from
the investor relations page of the company's corporate website at
http://ir.immunedesign.com/events.cfm. After the live webcast,
an archive of the presentation will be available on the company
website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the primary foci of Immune
Design's ongoing immuno-oncology clinical programs, are products of
its two synergistic discovery platforms, ZVex® and GLAAS®.
Immune Design has offices in Seattle and South San Francisco. For
more information, visit www.immunedesign.com.
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Sep 2023 to Sep 2024